Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779431 | 0.91 | CYP1A2 (0.40) | CYP1A2HSD17B10TNFTNKSTNKS2 | |
| SCHEMBL8779459 | 0.80 | TNF (0.45) | CYP1A2HSD17B10TNF | |
| SCHEMBL8421923 | 0.79 | TNF (0.56) | HSD17B10TNF | |
| SCHEMBL8421376 | 0.79 | TNF (0.56) | HSD17B10TNF | |
| SCHEMBL8779441 | 0.78 | CYP1A2 (0.39) | CYP1A2HSD17B10TNKSTNKS2PARP3 | |
| SCHEMBL7440983 | 0.72 | TNF (0.61) | TNF | |
| SCHEMBL8779410 | 0.70 | TNF (0.49) | HSD17B10TNFPPARGPPARA | |
| SCHEMBL8420151 | 0.68 | TNF (0.43) | CYP1A2TNF | |
| SCHEMBL8779469 | 0.68 | TNF (0.42) | CYP1A2TNF | |
| SCHEMBL7448361 | 0.67 | MEN1 (0.63) | HSD17B10TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0797437-A1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) | CELGENE CORPORATION (US) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996020705-A1 | IMMUNOTHERAPEUTIC IMIDES/AMIDES AND THEIR USE FOR REDUCING LEVELS OF TNF$g(a) | CELGENE CORPORATION (US) | 1996-07-11 | — | — | WO | disclosed |